These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 18990177)

  • 1. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
    Sella A; Sternberg CN; Skoneczna I; Kovel S
    BJU Int; 2008 Dec; 102(11):1607-9. PubMed ID: 18990177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
    Sella A; Sternberg C; Kovel S; Yarom N; Skoneczna I
    BJU Int; 2007 Sep; 100(3):533-5. PubMed ID: 17559560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
    Du J; Yang Q; Chen XS; Tian J; Yao X
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy.
    Nelius T; Klatte T; de Riese W; Filleur S
    Int Urol Nephrol; 2008; 40(1):97-104. PubMed ID: 17602304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
    J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
    Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
    Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
    Beer TM; Ryan CW; Venner PM; Petrylak DP; Chatta GS; Ruether JD; Chi KN; Young J; Henner WD;
    Cancer; 2008 Jan; 112(2):326-30. PubMed ID: 17960793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy.
    Nelius T; Filleur S
    Prostate; 2009 Dec; 69(16):1802-7. PubMed ID: 19676083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
    Nayyar R; Sharma N; Gupta NP
    Int J Urol; 2009 Sep; 16(9):726-31. PubMed ID: 19769656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
    Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
    Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience.
    Bamias A; Bozas G; Antoniou N; Poulias I; Katsifotis H; Skolarikos A; Mitropoulos D; Alamanis C; Alivizatos G; Deliveliotis H; Dimopoulos MA
    Eur Urol; 2008 Feb; 53(2):323-31. PubMed ID: 17445976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
    BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
    Nakabayashi M; Sartor O; Jacobus S; Regan MM; McKearn D; Ross RW; Kantoff PW; Taplin ME; Oh WK
    BJU Int; 2008 Feb; 101(3):308-12. PubMed ID: 18184327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel.
    Olbert PJ; Hegele A; Kraeuter P; Heidenreich A; Hofmann R; Schrader AJ
    Anticancer Drugs; 2006 Sep; 17(8):993-6. PubMed ID: 16940810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.
    Taplin ME; Xie W; Bubley GJ; Ernstoff MS; Walsh W; Morganstern DE; Regan MM
    J Clin Oncol; 2006 Dec; 24(34):5408-13. PubMed ID: 17135641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
    BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.